Effect of Fe3O4-magnetic nanoparticles on acute exercise enhanced KCNQ1 expression in mouse cardiac muscle

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 109-116

  Liu, Lijie ^a   Chen, Baoan ^b   Teng, Feixiang ^a   Shi, Lijuan ^a   Jing, Nan ^b   Wang, Li ^a   Chen, Ningna ^b   Xia, Guohua ^b   Li, Xiaomao ^c  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiac muscle; KCNQ1; Magnetic nanoparticles of FE3O4

Indexed keywords

IRON OXIDE; MAGNETIC NANOPARTICLE; POTASSIUM CHANNEL KCNQ1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXERCISE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART MUSCLE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWIMMING; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ELECTROMAGNETIC FIELDS; FERRIC COMPOUNDS; GENE EXPRESSION; HEART; KCNQ1 POTASSIUM CHANNEL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; PHYSICAL EXERTION;

MUS;

EID: 77951160364     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Whitesides GM. The 'right' size in nanobiotechnology. Nat Biotechnol. 2003;21(10):1161-1165.
2. Jeng HA, Swanson J. Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(12):2699-2711.
3. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18):3995-4021.
4. McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomed. 2007;2(2):153-167.
5. Naqvi S, Samim M, Dinda AK, et al. Impact of magnetic nanoparticles in biomedical applications. Recent Pat Drug Deliv Formul. 2009;3(2): 153-161.
6. Lai BB, Chen BA, Cheng J, et al. Daunorubicin-loaded magnetic nanoparticles of Fe(3)O(4) greatly enhance the responses of multidrugresistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17(2):345-351.
7. 4-magnetic nanoparticles on multi-drug resistance of ovarian carcinoma cells and its correlation with apoptosis-associated genes. Chin J Cancer. 2009;28(11):1158-1162.
8. 4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine. 2008;3(2):277-286.
9. Muldoon LL, Sàndor M, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery. 2005;57(4):785-796.
10. Dunning MD, Lakatos A, Loizou L, et al. Superparamagnetic iron oxidelabeled Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic resonance imaging and retain functional properties after transplantation into the CNS. J Neurosci. 2004;24(44):9799-9810.
11. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev. 2005;85(4):1205-1253.
12. Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science. 1988; 242(4881):1042-1045.
13. Charpentier F, Mérot J, Loussouarn G. Delayed rectifier K(+) currents and cardiac repolarization. J Mol Cell Cardiol. 2009 Aug 14. [Epub ahead of print].
14. Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, Blanar MA. KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci USA. 1997;94:4017-4021.
15. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Na Genet. 1996;12:17-23.
16. Walsh KB, Kass RS. Regulation of a heart potassium channel by protein kinase A and C. Science. 1988;242:67-69.
17. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS. Auto- nomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res. 2005;96(5): e25-e34.
18. 4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomedicine. 2009; 4: 201-208.
19. 4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res A. 2007;80(4):852-860.
20. Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. Physiology (Bethesda). 2005;20: 408-416.
21. Chen L, Kurokawa J, Kass RS. Phosphorylation of the A-kinase- anchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel. J Biol Chem. 2005;280(36):31347-31352.
22. Swan H, Toivonen L, Viitasalo M. Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome. European Heart Journal. 1998;19:508-513.
23. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61(6):467-477.
24. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316-327.
25. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomed. 2006;1(2):157-168.